Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cheplapharm gets rights to sell Orexigen's Mysimba in Germany, France, and Austria

Executive Summary

Orexigen Therapeutics Inc. granted Cheplapharm Arzneimittel GMBH rights to commercialize and distribute the obesity drug Mysimba (naltrexone HCl/bupropion HCl prolonged release) in Germany, France, and Austria.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies